Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Receives Average Rating of "Moderate Buy" from Brokerages

Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Get Free Report) has earned an average rating of "Moderate Buy" from the fifteen ratings firms that are covering the stock, Marketbeat reports. Four equities research analysts have rated the stock with a hold recommendation and eleven have given a buy recommendation to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $173.07.

Several research firms have weighed in on JAZZ. UBS Group lowered their price objective on shares of Jazz Pharmaceuticals from $117.00 to $113.00 and set a "neutral" rating for the company in a research report on Tuesday, July 2nd. Robert W. Baird dropped their price objective on shares of Jazz Pharmaceuticals from $160.00 to $154.00 and set an "outperform" rating for the company in a research report on Thursday, August 1st. Cantor Fitzgerald restated an "overweight" rating and set a $140.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, August 1st. Royal Bank of Canada decreased their price target on Jazz Pharmaceuticals from $175.00 to $174.00 and set an "outperform" rating on the stock in a report on Thursday, August 1st. Finally, JPMorgan Chase & Co. upped their price objective on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an "overweight" rating in a report on Monday, August 19th.

Jazz Pharmaceuticals Stock Performance

JAZZ traded up $0.38 on Friday, hitting $115.98. 365,743 shares of the stock traded hands, compared to its average volume of 661,447. The business has a fifty day moving average price of $109.54 and a two-hundred day moving average price of $112.79. The company has a current ratio of 2.37, a quick ratio of 1.90 and a debt-to-equity ratio of 1.36. Jazz Pharmaceuticals has a 52 week low of $99.06 and a 52 week high of $146.70. The firm has a market capitalization of $7.31 billion, a PE ratio of 23.91, a P/E/G ratio of 1.76 and a beta of 0.58.

Institutional Investors Weigh In On Jazz Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the stock. Rise Advisors LLC grew its stake in Jazz Pharmaceuticals by 2,255.6% during the first quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company's stock worth $26,000 after purchasing an additional 203 shares during the period. Versant Capital Management Inc lifted its stake in Jazz Pharmaceuticals by 13,450.0% during the 2nd quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company's stock valued at $29,000 after acquiring an additional 269 shares in the last quarter. Itau Unibanco Holding S.A. purchased a new position in Jazz Pharmaceuticals during the 2nd quarter worth $29,000. EverSource Wealth Advisors LLC boosted its holdings in Jazz Pharmaceuticals by 55.1% during the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company's stock worth $30,000 after purchasing an additional 97 shares during the last quarter. Finally, GAMMA Investing LLC boosted its stake in shares of Jazz Pharmaceuticals by 65.5% in the 2nd quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company's stock worth $31,000 after buying an additional 116 shares during the last quarter. Institutional investors own 89.14% of the company's stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.